Pharmacological studies on sufoxazine (Y-8894). II. Anti-anoxic effect.
- 1 January 1985
- journal article
- research article
- Published by Japanese Pharmacological Society in Folia Pharmacologica Japonica
- Vol. 86 (4) , 323-328
- https://doi.org/10.1254/fpj.86.323
Abstract
The anti-anoxic effect of sufoxazine was investigated in various cerebral anoxia models with mice, in comparison with those of various cerebroactive drugs. Sufoxazine reduced dose-dependently the duration of coma induced by a sublethal dose of KCN (1.8 mg/kg, i.v.), significantly stimulating recovery from the coma at 5 mg/kg, i.p. and 30 mg/kg, p.o. It also protected against a lethal dose of KCN (2.5 mg/kg, i.v.). Sufoxazine prolonged the survival time of mice subjected to hypobaric and normobaric hypoxia. Dihydroergotoxin and ifenprodil gave similar protection in the KCN-induced anoxia models, but produced adverse effects in the hypoxia models. Calcium hopantenate exerted similar but weak protection only at a dose as high as 300 mg/kg, i.p. These findings suggest that sufoxazine has an anti-anoxic action superior to those of the other cerebroactive drugs used.This publication has 2 references indexed in Scilit: